Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, announced on Thursday its financial results for the full year ended 31 December 2019.
The company reported revenue for the year ended 31 December 2019 at USD114.6m as compared to USD1.2bn in 2018.
The firm posted total operating costs and expenses for 2019 at USD554.7m as compared to USD505.4m in 2018.
Net loss for the year ended 31 December 2019 was USD440.7m or USD2.52 diluted loss per share as compared to net income of USD681.3m or USD3.78 diluted earnings per share in 2018.
Howard W Robin, Nektar's president and CEO, commented, 'Nektar's progress over the past year has established a strong foundation for growth, with a robust portfolio of clinical-stage immuno-oncology and immunology candidates addressing multiple therapeutic areas.'
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories